CHICAGO, May 16, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that Paul A. Friedman, M.D. was elected to its Board of Directors at the Company's 2013 Annual Meeting of Stockholders, which was held today. The Company also announced the departure of Dr. Dov Goldstein from its Board, effective as of this meeting. Dr. Goldstein did not stand for re-election.
"We are very pleased to welcome Dr. Friedman to our Board of Directors. He is a seasoned executive with extensive experience taking drug candidates from discovery through development to successful commercialization," said Richard De Schutter, Durata's Chairman of the Board. "We would also like to thank Dov for his many contributions and his commitment to Durata."
Dr. Friedman has served as President and Chief Executive Officer and member of the Board of Directors of Incyte Corporation, a publically traded biopharmaceutical company. From 1998 until October 2001, Dr. Friedman served as President of DuPont Pharmaceuticals Research Laboratories, a wholly owned subsidiary of DuPont Pharmaceuticals Company (formerly The DuPont Merck Pharmaceutical Company), from 1994 to 1998 he served as President of Research and Development of The DuPont Merck Pharmaceutical Company, and from 1991 to 1994 he served as Senior Vice President at Merck Research Laboratories. Prior to his work at Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr. Friedman is a diplomate of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. Dr. Friedman is also a director of Auxilium Pharmaceuticals, Inc.Dr. Friedman holds an M.D. from the Harvard Medical School and an A.B. in Biology from Princeton. He is also the author of over 100 scientific publications. About Durata Therapeutics Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, under investigation for the treatment of patients with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria.